Mineralys Therapeutics, Inc.

Mineralys Therapeutics presented new data from a post hoc analysis of its Launch-HTN and Advance-HTN trials, showing that lorundrostat was associated with significant reductions in heart failure risk biomarkers. The analysis, presented at ENDO 2026, indicated coordinated reductions in biomarkers of fibrosis and heart failure, suggesting lorundrostat may favorably modulate physiological processes driving heart failure. These findings provide biological plausibility and support further evaluation of lorundrostat's therapeutic potential in this setting. Lorundrostat is currently under review by the U.S. FDA, with a PDUFA target date of December 22, 2026.

Mineralys Therapeutics, Inc. announced its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. The company's fireside chat is scheduled for June 9, 2026, at 2:40 PM ET. A live webcast will be accessible via the company's investor relations website.

Mineralys Therapeutics announced that new data from a post hoc analysis of circulating proteomic data from its Launch-HTN and Advance-HTN trials will be featured in a late-breaking poster presentation at ENDO 2026. The data will highlight how lorundrostat modulates heart failure risk biomarkers in participants with uncontrolled hypertension. The presentation is scheduled for Sunday, June 14, 2026, in Chicago.

Mineralys Therapeutics priced an underwritten offering of 5,660,378 shares of its common stock at $26.50 per share, expecting gross proceeds of approximately $150.0 million and net proceeds of about $142.5 million. The offering, managed by BofA Securities, Goldman Sachs & Co. LLC, and Evercore Group L.L.C., is expected to close on June 4, 2026. The company plans to use the net proceeds to fund a portion of a $200.0 million upfront payment for the repurchase of a royalty obligation under its license agreement with Tanabe Pharma Corporation, complementing a recently announced $500 million committed debt facility.

Mineralys Therapeutics, Inc. entered into a fourth amendment to its License Agreement with Tanabe Pharma Corporation, terminating all future royalty payments for lorundrostat and securing an exclusive, worldwide, royalty-free, perpetual license. This strategic move involved a one-time cash payment of $200.0 million and potential additional commercial milestone payments of up to $355.0 million. Concurrently, the company secured a new five-year senior secured term loan facility for up to $500.0 million, with an initial $100.0 million drawn on June 2, 2026, providing significant capital for its operations.

Mineralys Therapeutics, Inc. announced the pricing of an underwritten public offering of 5,660,378 shares of its common stock at $26.50 per share, anticipating approximately $150.0 million in gross proceeds. The company plans to use the net proceeds to fund a portion of the $200.0 million upfront payment for the repurchase of a royalty obligation from Tanabe Pharma Corporation. This capital raise follows an earlier announcement of a $500 million committed debt facility, highlighting significant financial activities.

Mineralys Therapeutics announced a series of strategic financial transactions. The company repurchased all future royalty payments for lorundrostat from Tanabe Pharma Corporation for $200 million upfront and up to $100 million in commercial milestones, aiming to capture incremental value from future sales. Concurrently, Mineralys secured a $500 million senior secured term loan facility from Pharmakon Advisors, with $100 million funded at closing, significantly strengthening its balance sheet. Additionally, the company priced an underwritten offering of approximately $150 million of its common stock.

Mineralys Therapeutics presented new clinical data for lorundrostat from a post hoc analysis of its pivotal Phase 3 Launch-HTN trial. The analysis showed statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease (CKD), comparable to non-CKD participants. Additionally, lorundrostat significantly reduced urine albumin-to-creatinine ratio (UACR) in CKD participants with baseline albuminuria and demonstrated a favorable safety profile. The drug is currently under FDA review with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026.

Mineralys Therapeutics, Inc. held its 2026 annual meeting of stockholders on May 21, 2026. Stockholders approved the election of three Class III directors: Srinivas Akkaraju, Brian Taylor Slingsby, and Daphne Karydas, each for a three-year term. Additionally, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.

Mineralys Therapeutics announced that new data from its Phase 3 Launch-HTN trial for lorundrostat in patients with uncontrolled hypertension and chronic kidney disease (CKD) will be presented at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The oral presentation will highlight the efficacy and safety profile of lorundrostat, an aldosterone synthase inhibitor designed to reduce aldosterone levels. The company has completed six late-stage clinical trials, including the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials, which demonstrated robust and clinically meaningful reductions in systolic blood pressure with a favorable safety profile.